Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CREBBP | Q92793 | 5/20 | 0.35 |
| ▸ | BRD4 | O60885 | 10/20 | 0.35 |
| ▸ | BRD9 | Q9H8M2 | 5/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.34 |
| ▸ | BRD7 | Q9NPI1 | 2/20 | 0.32 |
| ▸ | BRD2 | P25440 | 1/20 | 0.32 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.32 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.32 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16651731 | 0.83 | BRD4 (0.46) | CREBBPBRD4BRD9PDE10ABRD7 | |
| SCHEMBL16651444 | 0.81 | CREBBP (0.38) | CREBBPBRD4PDE10A | |
| SCHEMBL19931013 | 0.80 | PDE4B (0.37) | CREBBPBRD4BRD9PDE10ABRD7 | |
| SCHEMBL29848786 | 0.78 | BRD4 (0.44) | CREBBPBRD4BRD9PDE10ABRD7 | |
| SCHEMBL16651614 | 0.78 | BRD4 (0.44) | CREBBPBRD4BRD9PDE10ABRD7 | |
| SCHEMBL25043154 | 0.77 | CREBBP (0.40) | CREBBPBRD4FGFR1 | |
| SCHEMBL19930818 | 0.77 | CREBBP (0.35) | CREBBPBRD4BRD9PDE10ABRD7 | |
| SCHEMBL16651201 | 0.75 | CREBBP (0.37) | CREBBPBRD4PDE10A | |
| SCHEMBL29848696 | 0.75 | CREBBP (0.37) | CREBBPBRD4PDE10A | |
| SCHEMBL19930933 | 0.74 | PDE4B (0.36) | CREBBPBRD4BRD9PDE10ABRD7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150183784-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2015-07-02 | — | — | US | disclosed |
| US-20150183784-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2015-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150183784-A1 | BROMODOMAIN INHIBITORS | BRD3, EP300, BRPF3 | CREBBP 45/4885BRD4 5/4885BRD9 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.